This company has been marked as potentially delisted and may not be actively trading. Aquinox Pharmaceuticals (AQXP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock AQXP vs. CALT, ZYME, SBTX, MBX, AVTE, NLTX, CYBN, BIOA, VIRI, and WHWKShould you be buying Aquinox Pharmaceuticals stock or one of its competitors? The main competitors of Aquinox Pharmaceuticals include Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), Cybin (CYBN), BioAge Labs (BIOA), Virios Therapeutics (VIRI), and Whitehawk Therapeutics (WHWK). Aquinox Pharmaceuticals vs. Its Competitors Calliditas Therapeutics AB (publ) Zymeworks Silverback Therapeutics MBX Biosciences Aerovate Therapeutics Neoleukin Therapeutics Cybin BioAge Labs Virios Therapeutics Whitehawk Therapeutics Aquinox Pharmaceuticals (NASDAQ:AQXP) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk. Do institutionals and insiders have more ownership in AQXP or CALT? 71.7% of Aquinox Pharmaceuticals shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 4.0% of Aquinox Pharmaceuticals shares are held by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media favor AQXP or CALT? In the previous week, Calliditas Therapeutics AB (publ) had 1 more articles in the media than Aquinox Pharmaceuticals. MarketBeat recorded 1 mentions for Calliditas Therapeutics AB (publ) and 0 mentions for Aquinox Pharmaceuticals. Aquinox Pharmaceuticals' average media sentiment score of 0.00 equaled Calliditas Therapeutics AB (publ)'saverage media sentiment score. Company Overall Sentiment Aquinox Pharmaceuticals Neutral Calliditas Therapeutics AB (publ) Neutral Is AQXP or CALT more profitable? Aquinox Pharmaceuticals has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Aquinox Pharmaceuticals' return on equity of -30.13% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Aquinox PharmaceuticalsN/A -30.13% -28.08% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% Which has preferable earnings & valuation, AQXP or CALT? Aquinox Pharmaceuticals has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAquinox Pharmaceuticals$25M19.02-$31.58MN/AN/ACalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62 Which has more risk and volatility, AQXP or CALT? Aquinox Pharmaceuticals has a beta of -7.37, meaning that its share price is 837% less volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. SummaryAquinox Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 6 of the 10 factors compared between the two stocks. Get Aquinox Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AQXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AQXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AQXP vs. The Competition Export to ExcelMetricAquinox PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$475.51M$791.77M$5.61B$9.84BDividend YieldN/A4.84%4.61%4.07%P/E RatioN/A1.1830.2725.74Price / Sales19.0226.06459.75115.79Price / CashN/A19.5638.2159.48Price / Book6.546.588.846.15Net Income-$31.58M-$4.98M$3.25B$265.06M Aquinox Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AQXPAquinox PharmaceuticalsN/A$20.20-4.3%N/A-37.1%$475.51M$25M0.008Gap DownCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180News CoverageZYMEZymeworks2.5165 of 5 stars$13.02+4.7%$21.43+64.6%+41.0%$907.27M$122.87M-8.68460SBTXSilverback TherapeuticsN/A$16.38-6.4%N/A+21.7%$590.63MN/A-6.7783High Trading VolumeMBXMBX Biosciences2.5583 of 5 stars$12.53+11.3%$37.63+200.3%N/A$418.80MN/A-2.7636News CoverageGap UpAVTEAerovate TherapeuticsN/A$7.40-1.2%N/A-87.8%$214.49MN/A-2.4720High Trading VolumeNLTXNeoleukin TherapeuticsN/A$20.35-4.1%N/A-38.2%$191.25MN/A-6.5490News CoverageHigh Trading VolumeCYBNCybin2.63 of 5 stars$7.63+5.1%$85.00+1,014.0%N/A$179.99MN/A-1.7450News CoveragePositive NewsBIOABioAge LabsN/A$4.48+3.2%N/AN/A$160.61MN/A0.00N/AVIRIVirios Therapeutics0.1147 of 5 stars$4.77-2.5%$5.00+4.8%+2,635.0%$91.86MN/A-17.675Gap UpWHWKWhitehawk TherapeuticsN/A$1.71+1.2%N/AN/A$80.59M$25.98M-28.5040 Related Companies and Tools Related Companies CALT Competitors ZYME Competitors SBTX Competitors MBX Competitors AVTE Competitors NLTX Competitors CYBN Competitors BIOA Competitors VIRI Competitors WHWK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AQXP) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquinox Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquinox Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access